Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Beelen, Karin ^a   Opdam, Mark ^a   Severson, Tesa M ^a   Koornstra, Rutger H T ^a   Vincent, Andrew D ^a   Wesseling, Jelle ^a   Muris, Jettie J ^a   Berns, Els M J J ^b   Vermorken, Jan B ^c   van Diest, Paul J ^d   Linn, Sabine C ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; TAMOXIFEN; TARGET OF RAPAMYCIN KINASE;

ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TAMOXIFEN; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84892573728     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3598     Document Type: Article

References (39)

1. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824. 10.1074/jbc.M010840200, 11139588.
2. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707-717.
3. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
4. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65:10992-11000. 10.1158/0008-5472.CAN-05-2612, 16322248.
5. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003, 222:147-166.
6. Stancovski I, Peles E, Ben LR, Lemprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. J Steroid Biochem Mol Biol 1992, 43:95-103. 10.1016/0960-0760(92)90192-L, 1356018.
7. Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B. Elevated insulin-like growth factor 1 receptor signaling induces anti-estrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011, 13:R52. 10.1186/bcr2883, 3218939, 21595894.
8. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413. 10.1172/JCI41680, 2898598, 20530877.
9. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011, 366:520-529.
10. Beelen K, Zwart W, Linn SC. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol 2012, 9:529-541. 10.1038/nrclinonc.2012.121, 22825374.
11. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010, 119:379-390. 10.1007/s10549-009-0575-y, 2810126, 19844788.
12. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
13. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826. 10.1093/annonc/mdl016, 16497822.
14. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107:10208-10213. 10.1073/pnas.0907011107, 2890442, 20479250.
15. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012, 66:105-143. 10.1016/j.phrs.2012.04.005, 22569528.
16. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ, Kuppuswamy D. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 2002, 277:23065-23075. 10.1074/jbc.M200328200, 11940578.
17. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412, 3465532, 23000897.
18. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002, 86:402-408. 10.1038/sj.bjc.6600072, 2375223, 11875707.
19. Vermorken JB, Burgers JMV, Taat CW, van de Slee PHT, Hennipman A, Norman JWR, Rozendaal KJ, Van Tinteren H, Huldij J, Benraadt J. Adjuvant tamoxifen in breast cancer: interim results of a comprehensive cancer center Amsterdam trial [Abstract 329, poster session III]. Breast Cancer Res Treat 1998, 50:283.
20. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
21. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012, 30:729-734. 10.1200/JCO.2011.36.2574, 22291085.
22. Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek) [in Dutch]. http://www.ccmo.nl/nl/niet-wmo-onderzoek, Central Committee on Research involving Human Subjects.
23. Dutch Federation of Biomedical Scientific Societies (Federatie van medisch wetenschappelijke verenigingen) [in Dutch]. http://www.federa.org/code-goed-gebruik-van-lichaamsmateriaal-2011, Dutch Federation of Biomedical Scientific Societies.
24. Guidelines for Scoring HercepTestTM - Breast. http://www.dako.com/38602_19feb10_herceptest_scoring_guidelines-breast_ihc.pdf.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
26. Siddiqui S, Rimm DL. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Res 2010, 12:113. 10.1186/bcr2782, 3046444, 21176180.
27. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132. 10.1200/JCO.2006.10.3523, 17513820.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184. 10.1093/jnci/dji237, 16106022.
29. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjold B, Stal O. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013, 137:397-406. 10.1007/s10549-012-2376-y, 3539073, 23242584.
30. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 2011, 126:93-99. 10.1007/s10549-010-1315-z, 21184268.
31. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002, 117:723-728. 10.1309/PEF8-GL6F-YWMC-AG56, 12090420.
32. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10:R89. 10.1186/bcr2187, 2614526, 18947395.
33. Al-Janabi S, Huisman A, van Diest PJ. Digital pathology: current status and future perspectives. Histopathology 2011, 61:1-9.
34. Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010, 16:1624-1633. 10.1158/1078-0432.CCR-09-1733, 20179234.
35. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476. 10.1200/JCO.2005.01.172, 15753463.
36. Beelen K, Opdam M, Severson T, Koornstra RHT, Vincent A, Wesseling J, Murris J, Berns EMJJ, Vermorken JB, van Diest PJ, Linn SC. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth 3 factor receptor 2 and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res 2013, in press.
37. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008, 14:2673-2680. 10.1158/1078-0432.CCR-07-1046, 18451231.
38. Bachelot T, Ferrero J, Cropet C, Bourgier C, Abadie-Lacourtoisie, Levy C. Translational studies within the TAMRAD randomized GINECO trial: evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer (mBC). Ann Oncol 2012, 23(Suppl 2):ii17-ii24.
39. Chavez-Mac GM, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN. A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NSABP S1207 [Abstract OT2-2-04]. Cancer Res 2012, 72(24):Supplement 3. doi: 10.1158/0008-5472.